CAR-T THERAPY

Carina Biotech is an Australian pre-clinical immunotherapy company established to research and develop chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers.

CAR-T therapy is a revolutionary new treatment option that uses a patient’s immune system to fight their cancer.

Carina is developing CAR-T and other adoptive cell therapies that can be used to treat solid cancers, are patient-specific and result in little, if any, off-cancer damage. Using its proprietary platforms, Carina is also developing technologies to improve access to, and infiltration of, solid cancers, and to enhance CAR-T cell manufacturing.

Learn more about CAR-T therapy.

Our name was inspired by a great journey and our Australian heritage.

It begins in the Argo Navis constellation (pictured here), which is very large with 160+ visible stars. In 1755 AD it was divided into the three modern constellations – Carina (Latin for hull), Puppis (poop deck) and Vela (the sails). The Carina constellation rises in the majestic southern sky over Australia.

Carina represents the ship in which Jason and the Argonauts (Ancient Greek mythological heroes) sailed in their quest to find the Golden Fleece. The Argo was said to have been constructed with the help of Athena, the Greek goddess associated with wisdom.

Our company’s vision ‘To create a future that defeats cancer’ runs in parallel to Jason’s quest to find the Golden Fleece.

We believe in the power of CAR-T technologies and other adoptive cell therapies to revolutionise cancer treatment and maximise patient outcomes. It was a happy coincidence that the first three letters of Carina form the acronym CAR = chimeric antigen receptor.

OUR TECHNOLOGIES

CAR-T cells that attack atypical solid cancer antigens

A genetic homing signal to attract CAR-T cells to solid tumours

Read more here >

OUR PEOPLE

Carina believes that it is imperative to foster a culture where every employee feels a sense of belonging and is encouraged to share ideas for succeeding in a diverse environment.

This starts with creating an equitable, diverse, and inclusive culture:

  • 60% of our team are women
  • 57% of our senior leadership team are women
  • 29% of our Board of Directors are women.

Management

Dr Deborah Rathjen, Chief Executive Officer & Managing Director

Professor Shaun McColl, VP, Chemokine Receptor Platform; Dr Jose Iglesias, Chief Medical Officer; Rohina Batra, Chief Financial Officer; Yulii Bogatyrenko, Chief Business Officer; Lina Jablonskis, Clinical Program Manager; Annabell Leske, Project Manager; Rachel Krebbekx, Executive Assistant

Read more here >

Board

Dr Leanna Read, Chair

Dr Deborah Rathjen, Chief Executive Officer & Managing Director; Michael Wyzga, Director; Dr Remus Vezan, Director; Dr Stephen Livesey, Director; Ray Wood, Director; Dr Michael Lamprecht, Director

Read more here >

Committees

Strategic, Finance Risk and Audit Committee (SFRAC)
Michael Wyzga (Chair), Ray WoodCharlie LathamSuzanne Ridding

Governance, People & Remuneration Committee (GPRC)
Stephen Livesey (Chair), Leanna Read, Alexander Gosling, Charlie Latham

Research Leaders

Professor Simon Barry, VP, CAR-T Manufacturing Program; Professor Claudine Bonder

Read more here >

Medical Advisory Board

Dr Jose Iglesias; Dr Roisin O’Cearbhaill; Dr Scott Kopetz; Associate Professor Jayesh Desai

Read more here >

KEY COLLABORATORS

Read more here >